miR-31-5p Regulates Type I Interferon by Targeting SLC15A4 in Plasmacytoid Dendritic Cells of Systemic Lupus Erythematosus
Shifei Li,Qijun Wu,Zhuyan Jiang,Yaguang Wu,Yuhong Li,Bing Ni,Jun Xiao,Zhifang Zhai
DOI: https://doi.org/10.2147/JIR.S383623
IF: 4.5
2022-12-06
Journal of Inflammation Research
Abstract:Shifei Li, 1 Qijun Wu, 1 Zhuyan Jiang, 1 Yaguang Wu, 1 Yuhong Li, 2 Bing Ni, 3 Jun Xiao, 4 Zhifang Zhai 1 1 Department of Dermatology, Southwest Hospital of Third Military Medical University, Chongqing, People's Republic of China; 2 Department of Cell Biology, Third Military Medical University, Chongqing, People's Republic of China; 3 Department of Pathophysiology, Third Military Medical University, Chongqing, People's Republic of China; 4 Department of Cardiovascular Medicine, Chongqing University Central Hospital, Chongqing, People's Republic of China Correspondence: Jun Xiao, Department of Cardiovascular Medicine, Chongqing University Central Hospital, Chongqing, People's Republic of China, Email Zhifang Zhai, Department of Dermatology, Southwest Hospital of Third Military Medical University, Chongqing, People's Republic of China, Email Background: Plasmacytoid dendritic cells (pDCs) are the main producers of type I interferon (IFN-I), and the excessive production of IFN-I is a hallmark of systemic lupus erythematosus (SLE). Both SLC15A4 and miR-31-5p are SLE susceptibility-related genes, and SLC15A4 has been implicated an important role in endolysosomal toll-like receptor (TLR) activation in pDCs. However, whether miR-31-5p exerts a regulating effect on SLC15A4 expression in pDCs is unclear. Methods: The expression of SLC15A4 and miR-31-5p in peripheral blood mononuclear cells (PBMCs) of SLE patients was measured by RT-qPCR analyses. The quantitative analysis of IFN-α secretion in the patients' serum was performed by ELISA assay. Luciferase-reporter assay was applied to confirm the interaction between miR-31-5p and SLC15A4. The expression of miR-31-5p, SLC15A4 and IFN-stimulated genes (ISGs, such as MX1, OAS1 and IFIT3) was detected by Western blot and RT-qPCR assays and further IRF5 phosphorylation was evaluated by immunofluorescence after transfected with miR-31-5p mimics or inhibitor in THP-1 and CAL-1 cells. Results: The expression of miR-31-5p was downregulated and negatively correlated with the overexpression of SLC15A4 in PBMCs of SLE patients. In addition to this, the secretion of IFN-α was overexpressed in sera of SLE and positively correlated with SLC15A4 level. We found that miR-31-5p directly targeted SLC15A4 and negatively regulated the expression of SLC15A4 in THP-1 and CAL-1 cells. In vitro inhibition of miR-31-5p increased the phosphorylation of IRF5 and the induction of ISGs stimulated by R848, overexpression of miR-31-5p get the reverse results. Conclusion: miR-31-5p might involve in SLE pathogenesis through regulating IFN-I expression by negatively regulating SLC15A4 to increase the levels of IFN-α and ISGs in pDCs. Keywords: systemic lupus erythematosus, miR-31-5p, SLC15A4, type I interferon, plasmacytoid dendritic cell, inflammation Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical presentations and primarily affects women of childbearing age. 1 As we know, type I IFN (IFN-I) is mostly produced by pDCs and plays a significant role in the pathogenesis of SLE. Solute carrier family 15 member 4 (SLC15A4) regulates lysosome antigen processing and endosomal toll-like receptors (TLRs) TLR7/9-mediated inflammatory responses. 2 In pDCs, SLC15A4 is essential for TLR to trigger the production of IFN-I, especially IFNα/β, which is involved in the pathogenesis of SLE. 3 Genetic, clinical and experimental data have strongly suggested that IFN-I plays an important role in SLE. Studies have also shown that SLC15A4 mutant C57BL/6-Fas(lpr) mice, in which pDCs were present but showed incapacitation to produce IFN-I in response to endosomal TLR ligands, which led to an absence of autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival. 4–6 Previous studies have demonstrated that both the proliferation and acquisition of activation markers were normal in SLC15A4-deficient B cells. 3 However, SLC15A4 or TASL (TLR adaptor interacting with SLC15A4 on the lysosome) deficiency caused defects in the activation of IRF5 but not in the MAPK or NF-kB pathway in pDC cell line CAL-1. 7 Recently, Kobayashi et al have reported that knocking down SLC15A4 expression impaired TLR7/8 or TLR9 triggered IFN-I production and decreased mTORC1 activity in CAL-1 cells. 8 These findings revealed that SLC15A4 plays a key role in pDCs and can be used as a potential therapeutic target. MicroRNAs (miRNAs) critically contribute to the progress of autoimmune diseases, 9 and the dysregulation of miRNA activity has been associated with the pathogenesis of SLE. 10 miRN -Abstract Truncated-
immunology